Bristol-Myers Squibb (BMS) has announced intentions to buy Celgene for $74bn. This transaction, the fourth largest such deal in pharma history, will give BMS access to several cancer franchises, including experimental cell therapies which attack tumours.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
The latest annual report from Trinity Partners has found that orphan disease drugs often perform poorly at launch and continue to underachieve after three years of sales. At the other end of the spectrum, the most successful drugs on the market were for non-orphan diseases such as cancer and HIV.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
STAT news have put together a great article assessing the need for health care systems to get on top of the payment issue quickly. Give it a read!
Consumers can contribute to medical breakthroughs and get rewarded for sharing health and genomic data while maintaining privacy and control.
The Science and Science Careers’ 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
The NIH has awarded inaugural funding to three institutions to establish a new genome centre for the All of Us Research Program.
The NIH has committed up to $45.5M to support its Somatic Cell Genome Editing programme. The money will make up a series of grants to be paid over the next four fiscal years.